Showing results (231-240 of 286) with videos related to

Sort By:
Pageof 29
JACS Au|July 26, 2024
Imidazolium-Based Sulfonating Agent to Control the Degree of Sulfonation of Aromatic Polymers and Enable Plastics-to-Electronics UpgradingChun-Yuan Lo, Kelsey P Koutsoukos, Dan My Nguyen, et al.
Plos One|June 4, 2016
The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic ProfilingSofia-Paraskevi Trachana, Eleftherios Pilalis, Nikos G Gavalas, et al.
Epilepsia|April 20, 2022
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndromePasquale Striano, Stéphane Auvin, Abigail Collins, et al.
Communications Medicine|May 26, 2023
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamstersCatherine Berry, Vincent Pavot, Natalie G Anosova, et al.
Vaccine|January 15, 2020
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01<sub>B</sub> vaccinationOlivier Van Der Meeren, Erik Jongert, Kelly E Seaton, et al.
Clinical Genitourinary Cancer|October 7, 2015
Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG)Aristotle Bamias, Stavros Peroukidis, Sophia Stamatopoulou, et al.
Cancer Management and Research|August 6, 2021
Referral for "Neoadjuvant Chemotherapy" for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and OutcomesAthanasios Dellis, Roubini Zakopoulou, Andromahi Kougioumtzopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumorsLee S Rosen, Razelle Kurzrock, Marilyn Mulay, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 10, 2024
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 StudyValentina De Giorgis, Kailash P Bhatia, Odile Boespflug-Tanguy, et al.
Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.
Pageof 29